Agomab Therapeutics
  • About Us
    • About Us
    • Executive Committee
    • Board of Directors
  • Our Science
    • Our Science
    • Publications
  • Our Pipeline
    • Our Pipeline
    • Ontunisertib (AGMB-129)
    • AGMB-447
    • AGMB-101
  • For Patients
    • Our Therapeutic Areas
    • Our Molecules
    • Clinical Trials
    • Expanded Access – Compassionate Use
    • Resources
  • News & Events
    • News Releases
    • Meet Us
  • Connect & Work with us
    • Contact us
    • Work with us
  • Investors
Agomab Therapeutics
  • About Us
    • About Us
    • Executive Committee
    • Board of Directors
  • Our Science
    • Our Science
    • Publications
  • Our Pipeline
    • Our Pipeline
    • Ontunisertib (AGMB-129)
    • AGMB-447
    • AGMB-101
  • For Patients
    • Our Therapeutic Areas
    • Our Molecules
    • Clinical Trials
    • Expanded Access – Compassionate Use
    • Resources
  • News & Events
    • News Releases
    • Meet Us
  • Connect & Work with us
    • Contact us
    • Work with us
  • Investors
Agomab In The News

Agomab in the News

EndPoints News – Sanofi backs fibrosis biotech Agomab as it raises $89M Series D

De Tijd – Big pharma loopt storm voor Vlaams biotechbedrijf Agomab

EndPoints News – Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds

De Tijd – 100 miljoen voor Gentse biotechbelofte die strijd aangaat met ziekte van Crohn

Fierce Biotech – Fierce Biotech’s 2022 Fierce 15

Fierce Biotech – Pfizer jumps into bed with Agomab, leading series B extension and lending support to Crohn’s program

De Tijd – Pfizer pompt miljoenen in Gentse biotechbelofte

Endpoints – The 20(+1) under 40: Your guide to the next generation of biotech leaders

InVivo – In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent

FierceBiotech – AgomAb raises $74M to develop regenerative pathway modulators.

Videos

Biotechbedrijf Agomab haalt bijna 90 miljoen dollar op

[presto_player id=14497]

Venture Company of the year

[presto_player id=14191]

  • Legal
  • Terms Of Use
Copyright © 2026 Agomab Therapeutics
×

You are leaving our website

This link will take you to a third-party website. The Company is not commenting on or approving the accuracy of the information available on this third-party website, and was not involved in the preparation of that information

Continue